XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and pot...

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed sales. The investigations focus on whether insiders are receiving preferential financial benefits and whether transaction terms may limit competing offers for Day One Biopharm...

Servier has agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The acquisition strengthens Servier's rare oncology portfolio, particularly in pediatric low-grade glioma, and expands its pipeline with programs targeting adult and pediatric cancers. The transac...

Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenues of $155.4 million (172% YoY growth) and Q4 revenues of $52.8 million. The company reaffirmed its 2026 U.S. OJEMDA revenue guidance of $225-$250 million and announced the acquisition of Mersana Therapeutics to expand its pipeline with Emi-Le for aden...

Day One Biopharmaceuticals (NASDAQ: DAWN) has successfully completed its acquisition of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition adds Emi-Le, a novel antibody-drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma, to Day One's clinical p...